Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-05-12
2011-12-20
Peng, Bo (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S006120
Reexamination Certificate
active
08080642
ABSTRACT:
The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo, into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering, in vivo, into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo, and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo. The SARS-CoV protein is also administered in an immunologically effective amount.
REFERENCES:
patent: 4597966 (1986-07-01), Zolton et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5032520 (1991-07-01), Binns et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5369026 (1994-11-01), Parker et al.
patent: 5389540 (1995-02-01), Makoff et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5643578 (1997-07-01), Robinson et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5661006 (1997-08-01), Brown et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5807551 (1998-09-01), Reynolds
patent: 5837693 (1998-11-01), German et al.
patent: 5861397 (1999-01-01), Wheeler
patent: 5994317 (1999-11-01), Wheeler
patent: 6004944 (1999-12-01), Rothman et al.
patent: 6022874 (2000-02-01), Wheeler
patent: 6080850 (2000-06-01), Darteil et al.
patent: 6096535 (2000-08-01), Darteil et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6224870 (2001-05-01), Segal
patent: 6231864 (2001-05-01), Birkett
patent: 6358512 (2002-03-01), Darteil et al.
patent: 6379966 (2002-04-01), Monahan et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6500432 (2002-12-01), Dalemans et al.
patent: 6586409 (2003-07-01), Wheeler
patent: 6632436 (2003-10-01), Segal
patent: 6670332 (2003-12-01), Wheeler
patent: 6696424 (2004-02-01), Wheeler
patent: 6710035 (2004-03-01), Felgner et al.
patent: 6867195 (2005-03-01), Felgner et al.
patent: 6875748 (2005-04-01), Manthorpe et al.
patent: 2001/0031264 (2001-10-01), Segal
patent: 2002/0045594 (2002-04-01), Volkin et al.
patent: 2002/0165172 (2002-11-01), Sallberg et al.
patent: 2003/0032615 (2003-02-01), Felgner et al.
patent: 2003/0191082 (2003-10-01), Wheeler
patent: 2004/0023911 (2004-02-01), Felgner et al.
patent: 2004/0157244 (2004-08-01), Budahazi et al.
patent: 2004/0157789 (2004-08-01), Geall
patent: 2004/0162256 (2004-08-01), Geall et al.
patent: 2004/0171572 (2004-09-01), Wheeler
patent: 2005/0002953 (2005-01-01), Herold
patent: 2005/0181357 (2005-08-01), Peiris et al.
patent: 2006/0257852 (2006-11-01), Rappuoli et al.
patent: 1548452 (2004-11-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 385 610 (1994-03-01), None
patent: 1 314 437 (2003-05-01), None
patent: 0 907 378 (2006-02-01), None
patent: 2000-302692 (2000-10-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 90/06764 (1990-06-01), None
patent: WO 00/02591 (2000-01-01), None
patent: WO 00/56282 (2000-09-01), None
patent: WO 00/57917 (2000-10-01), None
patent: WO 01/34801 (2001-05-01), None
patent: WO 02/00844 (2002-01-01), None
patent: WO 03/025003 (2003-03-01), None
patent: WO 2004/085650 (2004-10-01), None
patent: WO 2004/091524 (2004-10-01), None
patent: WO 2004/092208 (2004-10-01), None
patent: WO 2004/092360 (2004-10-01), None
patent: WO 2004/096842 (2004-11-01), None
patent: W02004/111187 (2004-12-01), None
patent: WO 2005/016238 (2005-02-01), None
Azevedo V et al. “Main features of DNA-based immunization vectors” Braz J Med Biol Res, Feb. 1999, vol. 32(2) 147-153.
Navas-Martin S et al. “Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development”. J Neurovirol. Apr. 2004;10(2):75-85.
Stockman L. et al “SARS: systematic review of treatment effects”. PLoS Med. Sep. 2006;3(9):e343. Review.
Kostopoulou E. et al. “A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene”. J Virol. May 2000;74(10):4839-52.
Nakamura Y et al. “Codon usage tabulated from international DNA sequence databases: status for the year 2000”. Nucleic Acids Res. Jan. 1, 2000;28(1):292.
Klavinskis et al. “Intranasal Immunization with Plasmid DNA—Lipid Complexes Elicits Mucosal Immunity in the Female Genital and Rectal Tracts” (1999, The Journal of Immunology,162: 254-262).
Anand, K., et al., “Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs,”Science 300:1763-1767, Originally published inSciencexpresspp. 1-10, American Association for the Advancement of Science (published online May 2003).
Donnelly, C.A., et al., “Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong,”Lancet 361:1761-1766, The Lancet Publishing Group (May 2003).
Drazen, M.D., J.M., “Case Clusters of the Severe Acute Respiratory Syndrome,”N. Engl. J. Med. 348:e6-7, Massachusetts Medical Society (published online Mar. 2003).
Drosten, C., et al., “Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome,”New Engl. J. Med. 348:1967-1976, Massachusetts Medical Society (published online Apr. 2003).
Glansbeek, H.L., et al., “Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus,”J. Gen. Virol. 83:1-10, Society for General Microbiology (Jan. 2002).
He, J.-F., et al., “Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China,” with supplementary text,Science 303:1666-1669, Originally published inSciencexpresspp. 1-32, American Association for the Advancement of Science (published online Jan. 2004).
Holmes, K.V., “SARS coronvirus: a new challenge for prevention and therapy,”J. Clin. Invest. 111:1605-1609, American Society for Clinical Investigation (Jun. 2003).
Holmes, K.V. and Enjuanes, L., “The SARS Coronavirus: A Postgenomic Era,”Science 300:1377-1364, American Association for the Advancement of Science (May 2003).
Kida, K., et al., “Selection of Antigenic Variants of the S Glycoprotein of Feline Infectious Peritonitis Virus and Analysis of Anitgenic Sites Involved in Neutralization,”J. Vet. Med. Sci. 61:935-938, Japanese Society of Veterinary Science (1999).
Ksiazek, T.G., et al., “A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome,”N. Engl. J. Med. 348:1953-1966, Massachusetts Medical Society (May 2003).
Little, S.F., et al., “Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine,”Vaccine 22:422-430, Elsevier Ltd. (Jan. 2004).
Peiris, J.S.M., et al., “Coronavirus as a possible cause of severe acute respiratory syndrome,”Lancet 361:1319-1325, The Lancet Publishing Group (published online Apr. 2003).
Poutanen, S.M., et al., “Identification of Severe Acute Respiratory Syndrome in Canada,”N. Engl. J. Med. 348:1995-2005, Massachusetts Medical Society (published online Mar. 2003).
Ruan, Y., et al., “Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins
Evans Thomas G.
Manthorpe Marston
Quong Melanie W.
Vilalta Adrian
Peng Bo
Sughrue & Mion, PLLC
Vical Incorporated
LandOfFree
Severe acute respiratory syndrome DNA compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Severe acute respiratory syndrome DNA compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Severe acute respiratory syndrome DNA compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4268137